Why the study?
Does phenprocoumon improve the stability of the anticoagulant effect compared to acenocoumarol in patients requiring anticoagulation?
Does phenprocoumon improve the stability of the anticoagulant effect compared to acenocoumarol in patients requiring anticoagulation?
Long-acting phenprocoumon provides a more stable anticoagulant effect and requires fewer dose adjustments than short-acting acenocoumarol.
May support phenprocoumon preference for stability in practice; leaves open confirmation by randomized trials before changing care.
Two comparable groups, each of which comprised 41 patients, were treated with long‐acting phenprocoumon and short‐acting acenocoumarol, respectively, for six months. When phenprocoumon was used, a significantly more stable anticoagulant effect was seen. This was reflected by a greater percentage of thrombotest values within the intended therapeutic zone ranging from 5 to 10% thrombotest activity, inclusive. Moreover, there was a difference in the facility with which patients could be kept in the therapeutic range: the number of alterations that had to be made in maintenance dose and control interval was less with phenprocoumon than with acenocoumarol.
No takes yet. Share an insight, caveat, or question.
Breed et al. (1969) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: